7.85
0.63 (8.73%)
| Previous Close | 7.22 |
| Volume | 2,078,670 |
| Price / Earnings (Forward) | 3.73 |
| Price / Sales | 2.17 |
| 52 Weeks Range |
| Profit Margin | -191.50% |
| Operating Margin (TTM) | -55.31% |
| Diluted EPS (TTM) | 29.61 |
| Quarterly Revenue Growth (YOY) | -14.10% |
| Current Ratio (MRQ) | 0.110 |
| Operating Cash Flow (TTM) | -145.74 M |
| Levered Free Cash Flow (TTM) | -114.08 M |
| Return on Assets (TTM) | -28.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Agenus Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -2.64 |
|
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.93% |
| % Held by Institutions | 33.95% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |